Ipsen: New Target Increase to 155 Euros at Closing
Ipsen's stock fell 1.22% on Wednesday, closing at 137.70 euros after reaching 139.40 euros the day before. Nevertheless, the pharmaceutical company's stock is still up 15.23% over three months and 13.71% over a year. In this context, analysts are adjusting their targets.
This Wednesday, Deutsche Bank significantly raised its target price on Ipsen, from 135 euros to 155 euros, while maintaining a 'buy' recommendation. This increase gives the stock a potential upside of about 12.5% compared to the last recorded price. Concurrently, BNP Paribas Exane also revised its approach two days earlier, on January 26, raising its target from 105 to 115 euros. However, the bank maintains an 'underperform' rating, reflecting a more cautious stance on the stock. These adjustments indicate an ongoing reevaluation of the potential of the group, which specializes in neuroscience and oncology, as the recent stock performance shows a marked upward trend.
Technical Analysis Indicates Strong Momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, Ipsen is significantly above its 20-day moving average, set at 129.08 euros, indicating favorable momentum. The stock thus shows a premium of nearly 7% compared to this intermediate threshold. However, the 14-day Relative Strength Index (RSI) is in the overbought zone at 79, a level suggesting a short-term overheating and could limit the immediate progress of the stock. This situation reflects strong investor enthusiasm but also calls for caution regarding potential corrective movements. The one-month volatility stands at 9.35, reflecting moderate fluctuations in a generally upward-oriented context.
"En 2025, Ipsen a enregistré une croissance solide de son chiffre d'affaires et de son résultat opérationnel."
Ipsen a publié ses résultats 2025 et T4 2025: chiffre d'affaires de 3 675,9 millions d'euros, croissance YoY de 8,1%; Résultat opérationnel des activités de 1 294,1 millions d'euros, marge de 35,2%; Résultat net consolidé IFRS de 444,5 millions d'euros; Bénéfice dilué par action IFRS de 5,32 euros; Cash-flow libre de 1 000,6 millions d'euros; Dividende par action de 1,40 euro.
Outlook / guidance
Expected revenue: Une croissance des ventes totales supérieure à 13,0 % à taux de change constant en 2026
Management commentary: Ipsen prévoit en 2026 une croissance des ventes totales supérieure à 13,0% à taux de change constant et une marge opérationnelle des activités supérieure à 35,0%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
